Posted by Michael Wonder on 13 Mar 2023
Heron Therapeutics announces Centers for Medicare & Medicaid Services granted pass through payment status for Aponvie
13 March 2023 - Heron Therapeutics today announced that CMS has approved transitional pass-through status for Aponvie (aprepitant) injectable emulsion, which will be established for three years beginning 1 April 2023 under C-code C9145.
Aponvie was approved by the US FDA for intravenous use in adults for the prevention of postoperative nausea and vomiting and became commercially available on 6 March 2023.
